The North America Long Read Sequencing Market is experiencing rapid expansion driven by technological advancements and increasing applications in genomics research. With leading companies such as Pacific Biosciences and Oxford Nanopore Technologies innovating in sequencing platforms, the market is set for significant growth. This report provides a comprehensive analysis of key growth drivers, current trends, market opportunities, revenue forecasts, regional shares, and recent developments influencing the long read sequencing landscape in North America from 2020 to 2035.
The economic impact of tariffs on "North America Long Read Sequencing Market".
Market Growth Drivers
Significant advancements in sequencing technology have fueled the growth of long read sequencing in North America. Companies such as Pacific Biosciences, with its Sequel II platform, have introduced highly accurate and higher throughput systems that enable the sequencing of longer and more complex DNA fragments. This is particularly advantageous for clinical diagnostics, genomic research, and structural variant detection, driving increased adoption among research institutions and pharmaceutical companies.
Rising prevalence of rare genetic disorders and cancers requiring comprehensive genomic profiling has necessitated more robust sequencing solutions. Leading laboratories are increasingly adopting long read sequencing to identify novel gene variants and structural rearrangements that are challenging to detect with short-read sequencing. For instance, recent collaborations between Oxford Nanopore Technologies and major academic medical centers in the US have highlighted a substantial uptick in clinical pilot programs using long read sequencing for improved diagnostic accuracy.
Market Trends
Integration of artificial intelligence and machine learning in sequence analysis is streamlining data interpretation, making it easier and faster to derive biological insights from large datasets. Illumina and other technology providers are investing in AI-based analytics, leading to enhanced accuracy in variant calling and genome assembly when using long read data. This trend is expected to accelerate discoveries in personalized medicine and agricultural genomics over the forecast period.
The emergence of portable and real-time sequencing platforms is revolutionizing genomics research. Oxford Nanopore’s MinION device has enabled field-based and point-of-care sequencing, supporting rapid outbreak response, environmental studies, and decentralized clinical diagnostics. This portability trend is attracting a broader user base beyond traditional research labs and is fostering collaborations between academic and public health stakeholders across North America.
Market Opportunity
The expansion of precision medicine initiatives by government and private organizations creates significant market opportunities. As the demand for accurate, long-read sequencing data grows in oncology, rare diseases, and pharmacogenomics, companies like Pacific Biosciences and Oxford Nanopore Technologies are poised to capitalize on large-scale sequencing projects and national genomics strategies.
Growing investments from venture capital and government grants for genomics infrastructure are opening new avenues for startups and established firms to innovate sequencing platforms and supporting analytics. Collaborations with university-based genomics centers present further potential for technological breakthroughs and market penetration.
North America Long Read Sequencing Market Revenue (USD Million), 2020-2035
The market revenue chart for North America Long Read Sequencing highlights sustained double-digit growth throughout the forecast period. Starting at USD 410 million in 2020, the market exhibits steady expansion, reaching an estimated USD 740 million by 2025 and is projected to soar to approximately USD 2,120 million by 2035. This upward trend is propelled by increased clinical applications, research funding, and broader use cases in diagnostics. The growth trajectory reflects continuous technological innovation and the scaling up of genomics initiatives by public and private sectors.
North America Long Read Sequencing Market by Region Share (%), 2025
The regional market share analysis for 2025 reveals that the United States dominates with 78% of the North America long read sequencing market, driven by advanced healthcare infrastructure and significant investments in genomics. Canada follows with a 15% share, benefiting from increasing research activities and government funding. Mexico accounts for 4%, while the rest of North America, including the Caribbean and Central America, holds the remaining 3%. This distribution underscores the technological leadership and market concentration in the US, with gradual uptake in neighboring regions.
Recent Developments
In May 2024, Pacific Biosciences announced the launch of its Revio system, a next-generation sequencing platform capable of delivering highly accurate long reads with significantly reduced turnaround time. The company reported partnerships with leading US genomics institutes to integrate Revio into clinical and research workflows, aiming to expand its customer base in oncology and rare disease diagnostics.
In April 2024, Oxford Nanopore Technologies secured a multi-million dollar contract with the US Centers for Disease Control and Prevention (CDC) to provide portable long read sequencing devices for field-based pathogen surveillance. This initiative is part of a broader push to improve rapid outbreak detection and response in remote areas across North America.
In March 2024, Illumina announced a strategic collaboration with several Canadian research universities to develop AI-powered bioinformatics tools specifically tailored for long read sequencing data analysis. The project intends to enhance the accuracy and speed of large-scale genomics studies and supports Canada’s evolving national precision medicine strategy.
Press Releases